Pricing Log in Create free account
Friday 6 November 2026 Export PBYI’s income statement to Excel — free account

Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024.

Revenue
+7.75%
EPS
+33.3%
Free cash flow
−88.5%
Total debt
−79.8%

Quarter to June 2026, against a year earlier

8.27 1.50 −15.35%
Market cap
$504.3M
P/E
15.3×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.02
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 3 — — — — 5 3 — 2 — —
Insider Ownership 21.32%

Capital & Financial Ratios $m

Size
Market Cap 504.33
Revenue ttm 231.24
Net income ttm 26.72
Free cash flow ttm 41.15
Net debt Q (93.90)
Valuation
P/E 15.31
Forward P/E 24.20
Price / sales 1.82
Forward P/S Powerpack
Price / FCF 14.74
Price / book 3.04
Financial health
Current ratio Q 2.91 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 42.14
Growth
Revenue growth Q +7.75% (above 0%: growing)
Operating income growth Q +14.30% (above 0%: growing)
EPS, this year −37.70% (below 0%: weak)
EPS, next year A −47.37% (below 0%: weak)
Revenue, next year A −1.04% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −9.64% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.5×, against a ten-year median of 1.0×; over the ten years it ranged from 0.4× in 2022 to 12.5× in 2018.
P/E against its own 10 years 64.29%
10-year low 10-year high
P/S against its own 10 years 79.81%
10-year low 10-year high
P/B against its own 10 years 20.75%
10-year low 10-year high
EV/Sales against its own 10 years 72.52%
10-year low 10-year high
EV/FCF against its own 10 years 51.63%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 96 101 100 94
Receivables 48 32 54 34
Inventory 7 9 6 13
Other 1 0 0 0
156 148 163 145
2023 2024 2025 Q'26
Payables 7 6 5 3
ST’ Debt 34 45 23 —
Other 1 3 2 1
99 96 81 50

Compound Annual Growth %

10y 5y 3y
Sales — 0.29% 0.05%
Cash Flow 0.00% 122.13% 0.00%
Earnings 0.00% 0.00% 2,396.29%
Book Value (4.47%) 0.00% 82.03%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.10 Actual 0.19

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.09 0.21 Beat by 0.12
Q4 FY25 0.24 0.29 Beat by 0.05
Q1 FY26 −0.13 −0.04 Beat by 0.09
Q2 FY26 0.10 0.19 Beat by 0.09
Q3 FY26 0.11 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.07) 0.16 — — —
’25 0.06 0.12 0.17 0.26 0.61
’24 (0.10) (0.09) 0.41 0.39 0.62
’23 0.03 0.05 0.12 0.26 0.45
’22 (0.08) 0.21 (0.01) (0.12) 0.00
’21 0.40 (0.13) (1.09) 0.10 (0.72)
’20 (0.43) 0.08 (0.79) (0.38) (1.52)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 45 57 — — —
’25 46 52 54 75 228
’24 44 47 81 59 230
’23 53 55 56 72 236
’22 46 60 57 66 228
’21 98 53 46 55 253
’20 51 71 51 53 225
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 15 2 — — —
’25 4 14 10 14 42
’24 11 1 11 16 39
’23 3 3 11 10 27
’22 (27) (14) 17 8 (16)
’21 16 0 10 (5) 21
’20 (12) 16 2 (6) 1
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 15 2 — — —
’25 4 14 10 14 42
’24 11 1 11 16 39
’23 (10) 3 11 10 14
’22 (27) (14) 17 1 (23)
’21 16 0 10 (5) 21
’20 (12) 6 2 (6) (9)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 28 251 272 225 253 228 236 230 228 231 +30.2% 226 229 230 +0.2%
Gross margin, % 0.00 79.87 86.21 86.48 82.51 74.84 75.84 73.40 72.06 74.53 74.83 +74.5 pt
EBT (276) (292) (114) (76) (60) (29) 0 23 24 36 31 n/m
EBT margin, % 0.00 (1,054.56) (45.24) (27.75) (26.56) (11.38) 0.20 9.62 10.46 15.67 13.48 +15.7 pt
Net income (276) (292) (114) (76) (60) (29) 0 22 30 31 27 n/m
Per share, $
Per share, $ Revenue 0.00 0.74 6.62 7.02 5.69 6.23 5.10 5.00 4.74 4.57 4.54 n/m
Earnings (8.29) (7.85) (2.99) (1.95) (1.52) (0.72) 0.00 0.46 0.62 0.62 0.54 n/m
Cash flow (4.26) (4.64) (0.64) 0.58 0.02 0.51 (0.35) 0.57 0.80 0.84 0.81 n/m
Capex (0.22) (1.36) (0.02) (0.01) (0.25) 0.00 (0.16) (0.27) 0.00 0.00 0.00 (43.0%)
Free cash flow (4.47) (6.00) (0.65) 0.57 (0.23) 0.51 (0.51) 0.30 0.80 0.83 0.81 n/m
Book value 6.30 1.43 0.90 0.45 (0.15) (0.06) 0.48 1.13 1.89 2.61 2.72 (9.3%)
Shares, m 33 37 38 39 40 41 45 47 49 50 51 +4.6%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 1,966.67 9.85 5.00 9.44 15.31 221.2
P/S — 0.00 3.08 1.25 1.80 0.49 0.81 0.91 0.64 1.30 1.82 1.1
P/B — 64.61 22.51 19.43 0.00 0.00 8.54 4.00 1.61 2.28 3.04 13.7
EV/Sales — 0.00 3.02 1.16 1.79 0.53 0.90 0.92 0.50 1.01 1.51 1.1
EV/FCF — (19.73) (30.69) 14.71 (41.98) 12.94 (8.88) 15.14 4.35 7.91 12.23 (5.1)
Cash, $m
Cash, $m Operating cash flow (142) (172) (24) 22 1 21 (16) 27 39 42 41 n/m
Capex (7) (50) (1) 0 (10) — (7) (13) 0 0 0 (40.2%)
Free cash flow (149) (223) (25) 22 (9) 21 (23) 14 39 42 41 n/m
Balance, $m
Balance, $m Working capital 199 48 136 75 32 30 57 57 52 81 95 (9.5%)
Net debt (229) (33) (14) (23) (4) 10 21 4 (34) (77) (94) (11.4%)
Shareholders’ equity 210 53 34 17 (6) (2) 22 53 92 130 139 (5.2%)
Returns, %
Returns, % ROA (112.06) (139.59) (53.49) (30.60) (25.04) (12.37) 0.00 9.54 13.64 14.48 13.78 +126.5 pt
ROIC 0.00 (910.03) (284.82) 0.00 0.00 11.10 34.49 35.69 33.25 43.78 42.61 +43.8 pt
ROE (132.75) (221.91) (259.28) (292.05) (1,042.29) 693.73 0.02 57.54 41.60 27.97 21.97 +160.7 pt
People
People Employees 160 318 272 269 267 196 192 185 172 179 — +1.3%
Revenue/emp, $m 0.00 0.09 0.92 1.01 0.84 1.29 1.19 1.27 1.34 1.28 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Puma Biotechnology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ENTX Entera Bio Ltd. $520.0M — (loss-making) — (loss-making) +200.00% (above 0%: growing) n/m −108.86% (below 0%: shrinking) 0.00% 0.00% Compare
FTH Faeth Therapeutics, Inc. $514.8M — (loss-making) — — n/m −262.66% (below 0%: shrinking) 0.00% 0.00% Compare
NGNE Neurogene Inc. $513.3M — (loss-making) — (loss-making) — n/m −22.97% (below 0%: shrinking) 100.00% 0.00% Compare
CLYM Climb Bio, Inc. $509.5M — (loss-making) — — n/m +3.73% (above 0%: growing) — 0.00% Compare
YDES YD Bio Limited $508.7M — — — — — — — Compare
SLBT SL SCIENCE HLDG $504.7M — — — — — — — Compare
PBYI Puma Biotechnology, Inc. $504.3M 15.3× 24.2× +7.75% (above 0%: growing) +33.33% (above 0%: growing) −88.45% (below 0%: shrinking) 77.92% 13.42%
OVID Ovid Therapeutics $503.9M — (loss-making) — (loss-making) +463.85% (above 0%: growing) n/m −268.54% (below 0%: shrinking) 100.00% (2,141.61%) Compare
CAPR Capricor Therapeutics, Inc. $500.0M — (loss-making) — (loss-making) −7.92% (below 0%: shrinking) n/m −72.88% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $509.1M — — +200.00% — −90.87% 100.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 28 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 3.06m 4.43m 58.00
2024 3.97m 2.55m 30.00
2023 2.94m 2.80m 42.00
2022 2.53m 3.25m 41.00
2021 18.45m 14.67m 30.00

Ownership

Directors and executive officers, together 22.20%
Alan H. Auerbach 19.60%
Acorn Capital Advisors 7.70%
BlackRock Fund Advisors 5.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Puma Biotechnology, Inc. (PBYI) Latest News

6 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript

5 Nov

Impact 3 · · Business Wire

22 Oct

Impact 3 · · Business Wire

20 Oct

Impact 4 · · Zacks

18 Sep

Impact 3 ·

17 Sep

Impact 3 ·

14 Aug

Impact 4 · · The Motley Fool transcript

7 Aug

Impact 4 ·
Impact 4 · · Moby transcript
Impact 4 · transcript
Impact 3 · · MarketBeat

6 Aug

Impact 3 ·
Impact 3 ·

30 Jul

Impact 3 ·

11 May

Impact 4 · · Simply Wall St.

8 May

Impact 4 · · The Motley Fool transcript
Impact 4 ·
Impact 3 · · MarketBeat
Impact 3 · · Moby

7 May

Impact 4 · · Business Wire
Impact 3 · · Zacks

18 Mar

Impact 3 · · Zacks

27 Feb

Impact 4 · · Zacks
Impact 4 · · Moby
Impact 4 · · MarketBeat
Impact 4 · · GuruFocus.com

26 Feb

Impact 4 · · Zacks
Impact 4 · · The Motley Fool transcript
stockrow.com/PBYI · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com